Sidley Represents Axsome Therapeutics in its Acquisition of Global Rights to Balipodect from Takeda
Sidley represented Axsome Therapeutics, Inc. (Nasdaq: AXSM), in its acquisition of exclusive global rights from Takeda Pharmaceutical Co. Ltd. to TAK-063 (balipodect), a novel and selective inhibitor for the treatment of schizophrenia and Tourette syndrome. Under the agreement, Takeda received an upfront payment and is eligible to receive royalties and payments related to development, regulatory, and commercial milestones. Axsome plans to begin Phase 3 trial-enabling activities for the schizophrenia indication in 2026.
